MSP58 Knockdown Inhibits the Proliferation of Esophageal SCC in Vitro and in Vivo

Chunsheng Xu,Jian-yong Zheng,Hai-long Zhang,Huadong Zhao,Jing Zhang,Guo-Qiang Wu,Lin Wu,Qing Wang,Wei-Zhong Wang,Jian,Zhang

2012-01-01

Abstract:Esophageal carcinoma (EC) is one of the most fatal cancers in the gastrointestinal tract of the digestive system. Epidemiological evidence reveals that, worldwide, it is the fifth most common cause of death from cancer in men and the eighth most common cause of death from cancer in women (Jemal et al., 2011). The highest incidence rate is found in developing countries, particularly in China (Pickens et al., 2003; Yu et al., 2010; Jemal et al., 2011). Esophageal squamous cell carcinoma (ESCC) is one of the most common pathologic types in EC (about 90%) (Stoner et al., 2001; Enzinger et al., 2003). Although great improvements have been made in the diagnosis, surgical treatment, chemotherapy and radiotherapy of esophageal cancer, the overall survival rate of esophageal cancer remains poor, with a 5-year survival of 15–34% (Allum et al., 2009; Sjoquist et al., 2011; Siegel et al., 2012; Xu et al., 2012). Therefore, it is extremely necessary to investigate the molecular mechanisms of the development of EC. Further studies, which aim to identify novel tumorrelated genes and clarify of their roles in EC, will help to elucidate the mechanism of the initiation and progression of esophageal cancer.